Equities analysts predict that Tabula Rasa HealthCare Inc (NASDAQ:TRHC) will report earnings per share of $0.07 for the current fiscal quarter, Zacks Investment Research reports. Six analysts have issued estimates for Tabula Rasa HealthCare’s earnings, with the highest EPS estimate coming in at $0.16 and the lowest estimate coming in at ($0.02). Tabula Rasa HealthCare reported earnings of $0.10 per share during the same quarter last year, which would suggest a negative year over year growth rate of 30%. The business is expected to report its next quarterly earnings report on Tuesday, May 14th.

On average, analysts expect that Tabula Rasa HealthCare will report full-year earnings of $0.86 per share for the current fiscal year, with EPS estimates ranging from $0.62 to $1.41. For the next fiscal year, analysts anticipate that the business will post earnings of $1.29 per share, with EPS estimates ranging from $0.75 to $2.09. Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that cover Tabula Rasa HealthCare.

Tabula Rasa HealthCare (NASDAQ:TRHC) last issued its earnings results on Thursday, February 28th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.07). The company had revenue of $57.31 million for the quarter, compared to analyst estimates of $55.70 million. Tabula Rasa HealthCare had a negative net margin of 23.14% and a positive return on equity of 7.76%.

A number of equities research analysts have issued reports on the stock. Zacks Investment Research raised shares of Tabula Rasa HealthCare from a “sell” rating to a “hold” rating in a research note on Thursday, December 6th. Piper Jaffray Companies reissued an “overweight” rating and set a $80.00 target price on shares of Tabula Rasa HealthCare in a research note on Thursday, December 6th. BidaskClub lowered shares of Tabula Rasa HealthCare from a “sell” rating to a “strong sell” rating in a research note on Saturday, February 9th. Oppenheimer decreased their target price on shares of Tabula Rasa HealthCare from $97.00 to $88.00 and set an “outperform” rating for the company in a research note on Wednesday, March 6th. Finally, First Analysis raised shares of Tabula Rasa HealthCare from an “outperform” rating to a “strong-buy” rating and set a $58.33 target price for the company in a research note on Monday, March 11th. Three research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $83.48.

Shares of NASDAQ:TRHC traded down $0.40 during trading on Monday, reaching $59.24. 276,055 shares of the company traded hands, compared to its average volume of 417,782. The firm has a market capitalization of $1.26 billion, a P/E ratio of 174.24 and a beta of 1.66. Tabula Rasa HealthCare has a 1-year low of $35.50 and a 1-year high of $91.16. The company has a quick ratio of 0.79, a current ratio of 0.84 and a debt-to-equity ratio of 0.32.

In related news, insider Andrea Carolan Speers sold 1,022 shares of Tabula Rasa HealthCare stock in a transaction on Thursday, January 3rd. The shares were sold at an average price of $58.08, for a total value of $59,357.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Calvin H. Knowlton sold 8,000 shares of Tabula Rasa HealthCare stock in a transaction on Monday, January 7th. The shares were sold at an average price of $63.06, for a total transaction of $504,480.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 54,057 shares of company stock valued at $3,175,138. 14.00% of the stock is owned by company insiders.

Several hedge funds have recently added to or reduced their stakes in TRHC. First Mercantile Trust Co. bought a new position in Tabula Rasa HealthCare in the 4th quarter worth $39,000. TCI Wealth Advisors Inc. raised its holdings in Tabula Rasa HealthCare by 1,600.0% in the 4th quarter. TCI Wealth Advisors Inc. now owns 850 shares of the company’s stock worth $54,000 after acquiring an additional 800 shares during the period. Quantamental Technologies LLC bought a new position in Tabula Rasa HealthCare in the 4th quarter worth $64,000. Oppenheimer Asset Management Inc. bought a new position in Tabula Rasa HealthCare in the 4th quarter worth $135,000. Finally, Riverhead Capital Management LLC raised its holdings in Tabula Rasa HealthCare by 100.0% in the 3rd quarter. Riverhead Capital Management LLC now owns 2,600 shares of the company’s stock worth $211,000 after acquiring an additional 1,300 shares during the period. 78.00% of the stock is owned by institutional investors and hedge funds.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. It offers medication risk management, pharmacy cost management, and medicare risk adjustment services. The company offers its technology-enabled products and services to prescribers, pharmacists, and healthcare organizations for medication risk management and risk adjustment.

See Also: The Structure of a Futures Contract

Get a free copy of the Zacks research report on Tabula Rasa HealthCare (TRHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.